NairB., RavalG., MehtaP.Tnf-alpha inhibitor etanercept and hematologic malignancies: report of a case and review of the literature. Am J Hematol.2007; 82: 1022–4.
2.
RosenfeldC.S., BedellC.Pilot study of recombinant human soluble tumor necrosis factor receptor (TNFR: Fc) in patients with low risk myelodysplastic syndrome. Leuk Res.2002; 26: 721–4.
3.
ChenM., HollandM.J., MirM.R.Frequency of thrombocytopenia in psoriasis patients treated with tumor necrosis factor-α inhibitors. J Drugs Dermatol.2011; 10: 280–4.
4.
LiuY.C., ItoY., HsiaoH.H.Risk factor analysis in myelodysplastic syndrome patients with del(20q): prognosis revisited. Cancer Genet Cytogenet.2006; 171: 9–16.
5.
WarlickE.D., SmithB.D.Myelodysplastic syndromes: review of pathophysiology and current novel treatment approaches. Curr Cancer Drug Targets.2007; 7: 541–58.
